Private Advisor Group LLC Has $3.66 Million Position in CytomX Therapeutics, Inc. (CTMX)

Private Advisor Group LLC lifted its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 85.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 185,187 shares of the biotechnology company’s stock after purchasing an additional 85,187 shares during the quarter. Private Advisor Group LLC owned 0.48% of CytomX Therapeutics worth $3,661,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Macquarie Group Ltd. bought a new position in CytomX Therapeutics in the 3rd quarter worth about $107,000. Legal & General Group Plc increased its stake in CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,434 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in CytomX Therapeutics in the 1st quarter worth about $190,000. Cubist Systematic Strategies LLC bought a new position in CytomX Therapeutics in the 2nd quarter worth about $174,000. Finally, Voya Investment Management LLC bought a new position in CytomX Therapeutics in the 2nd quarter worth about $203,000. Institutional investors own 63.18% of the company’s stock.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) opened at $20.79 on Tuesday. CytomX Therapeutics, Inc. has a 1 year low of $10.40 and a 1 year high of $24.67.

A number of equities analysts have weighed in on CTMX shares. Cowen restated a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Nomura upped their target price on CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Bank of America restated a “buy” rating and issued a $30.00 target price (up from $28.00) on shares of CytomX Therapeutics in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald started coverage on CytomX Therapeutics in a research note on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $31.88.

In other news, CEO Sean A. Mccarthy sold 19,120 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $24.13, for a total transaction of $461,365.60. Following the transaction, the chief executive officer now directly owns 23,365 shares in the company, valued at approximately $563,797.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Robert I. Tepper sold 20,000 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $18.00, for a total value of $360,000.00. Following the transaction, the insider now owns 54,293 shares in the company, valued at $977,274. The disclosure for this sale can be found here. Insiders have sold a total of 156,169 shares of company stock worth $3,488,563 over the last quarter. Corporate insiders own 8.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Private Advisor Group LLC Has $3.66 Million Position in CytomX Therapeutics, Inc. (CTMX)” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/12/05/private-advisor-group-llc-has-3-66-million-position-in-cytomx-therapeutics-inc-ctmx.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply